Intersect ENT, Inc.

Intersect ENT, Inc.

Intersect ENT, Inc.

Overview
Date Founded

2003

Headquarters

1555 Adams Drive,Menlo Park, CA 94025

Type of Company

Public

Employees (Worldwide)

393

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Medical Products & Equipment

Company Description

Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.

Contact Data
Trying to get in touch with decision makers at Intersect ENT, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Interim President & Chief Executive Officer

President, Chief Executive Officer & Director

Chief Financial Officer & Principal Accounting Officer

Chief Operating Officer

Secretary & General Counsel

Chief Commercial Officer

Chief People Officer

Chief Strategy Officer

Vice President, Clinical Affairs

Vice President, Regulatory Affairs

Board of Directors

Former Interim President & Chief Executive Officer at Intersect ENT, Inc.

Founder at Auris Surgical Robotics, Inc.

President, Chief Executive Officer & Member of the Board of Directors at HeartFlow, Inc.

Former President at Johnson & Johnson

President, Chief Executive Officer & Director at Intersect ENT, Inc.

Member-Deans Council at Indiana University - Kelley School of Business

Member, Payer Advisory Team at Prognos Health, Inc.

Paths to Intersect ENT, Inc.
Potential Connections via
Relationship Science
You
Intersect ENT, Inc.
Owners & Shareholders
Details Hidden

Deerfield Management Co. focuses on investments in growth stocks across the healthcare sector. They target companies with sound fundamentals, long-term earnings growth potential and the potential to capitalize on market trends. Deerfield's approach is based on extensive fundamental research into healthcare sector assets and investment opportunities. They invest mainly in US companies or companies that issue securities available in US public markets. Although this is their focus, there is no geographic limitation on investments and Deerfield may invest outside the US when situations warrant. Their funds generally pursue one of 3 strategies: Large-Cap, Special Situations and Private Design.Deerfield's Large-Cap strategy invests mainly in debt and equity securities, including exchange traded derivative securities, of publicly-traded companies in the healthcare sector. The strategy seeks capital appreciation through a combination of security selection based on fundamental analysis, diversification through investments in stock, debt and derivatives and a mix of long and short positions.The firm's Special Situations strategy emphasizes investments in publicly traded healthcare companies with smaller market-caps. At least 90% of investments must in healthcare companies, and essentially all investments are healthcare related. Investments include equity, debt, royalties or other assets, some of which may have limited liquidity. The strategy makes both long and short investments and may utilize leverage.Deerfield's Private Design strategy invests in public and private healthcare companies using privately created instruments, structures and transactions. This may include, but is not limited to, joint ventures, project financing, contracting for revenue streams, purchasing products/services outright (including intellectual property), participating in LBOs, restructurings and outright buyouts, and developing/participating in the development and sale of therapeutics, medical devices and healthcare products/services.

Details Hidden

HealthCor Management's funds seek to preserve capital and generate risk-adjusted capital growth. The funds pursue a fundamental-driven long/short equity strategy with a primary focus on the global healthcare and life sciences sector. HealthCor employs a bottom-up fundamental selection of best long and short ideas. The firm conducts daily monitoring of top-down, portfolio-level analysis, including the following: concentration of investments: liquidity; price target and stop loss monitoring, leverage, and hedging. In addition, HealthCor has adopted a Socially Responsible Investment Policy outlining their practical integration of environmental, social and governance (\"ESG\") considerations into their investment process.

Details Hidden

First Light Asset Management LLC is a private company headquartered in Edina, MN, that provides investment advice. The firm was founded in 2013 by Matthew Paul Arens and Brett Thomas Johnson. Matthew Paul Arens has been the CEO since then.

Recent Transactions
Details Hidden

Intersect ENT, Inc. issued Common Stock

Details Hidden

Intersect ENT, Inc. issued Common Stock

Details Hidden

Intersect ENT, Inc. raised money in a private placement transaction

Transaction Advisors
Underwriter

Advised onIntersect ENT, Inc. issued Common Stock

Underwriter

Advised onIntersect ENT, Inc. issued Common Stock

Underwriter

Advised onIntersect ENT, Inc. issued Common Stock

Associate

Advised onIntersect ENT, Inc. issued Common Stock

Co-Chair, Tax Practice Group

Advised onIntersect ENT, Inc. issued Common Stock

Associate

Advised onIntersect ENT, Inc. issued Common Stock

Advisors & Consultants
Advisor

Assurance Partner at Ernst & Young LLP

Key Stats and Financials As of 2018
Market Capitalization
$536M
Total Enterprise Value
$753M
Earnings Per Share
$-0.76
Revenue
$108M
Net Profit
$-22.9M
EBITDA
$-23.1M
EBITDAMargin
-21.32%
Total Debt
$0
Total Equity
$121M
Enterprise Value Sales
6.95x
TEVNet Income
-32.87x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
21.49%
Five Year Compounded Annual Growth Rate Of Revenue
43.33%
Investors
Details Hidden

Medtronic was founded in 1949 as a medical equipment repair shop by Earl Bakken and his brother-in-law, Palmer Hermundslie. Since then, we've grown into a multinational company that uses technology to transform the way debilitating, chronic diseases are treated.Our first life-changing therapy – a wearable, battery-powered cardiac pacemaker – was the foundation for dozens more Medtronic therapies that use our electrical stimulation expertise to improve the lives of millions of people. Over the years, we adapted additional technologies for the human body, including radio frequency therapies, mechanical devices, drug and biologic delivery devices, and diagnostic tools. Today, our technologies are used to treat more than 30 chronic diseases affecting many areas of the body.

Details Hidden

Kleiner Perkins Caufield & Byers (KPCB) focuses on investments in the life sciences, biodefense, green technology, information technology and companies with new technologies related to the iPhone and iPod touchpad platform.The firm's information technology investments focus on the consumer, enterprise, semiconductors, security and communications industries. They invest primarily in early-stage ventures that are incubating new companies with proven entrepreneurs and good ideas.KPCB's life sciences investments include medical devices, drugs, vaccines, personalized medicine, diagnostics and healthcare information technology and services. Their pandemic and biodefense investment initiative focuses on investments in companies with innovations in disease surveillance, rapid diagnostics, new vaccine technology, portable and less expensive manufacturing of vaccines and new antiviral drugs.The firm's iFund invests in market-changing ideas and products that extend the iPhone and iPod touch platform. The Fund invests across all sizes and stages. KPCB targets investments in companies that are developing applications, services and components. Their specific areas of interest include: location-based services, social networking, eCommerce (including advertising and payments), communication and entertainment.

Details Hidden

Harmony Partners is a bi-coastal boutique venture capital firm whose mission is to enable software entrepreneurs to optimize expansion stage financings. With offices in New York City and Silicon Valley, Harmony fills a gap in the market for entrepreneur-friendly expansion stage capital. Harmony eliminates the deal constraints of traditional growth equity firms: $30-50 million minimum check sizes, >20% ownership targets, mandatory board seats, vetoes on M&A events, and multi-layered decision making. As such, the firm works collaboratively with Founders to craft the ideal financing that minimizes dilution, saves the company time and effort, while accommodating insider appetite and making room for strategics if relevant. Harmony has a longer-term orientation than most funds because the majority of its capital comes from seven billionaire family offices, and as result, the firm looks to buy in the IPO, not sell. Since 1993, the founding partners have invested in over 80 technology-driven companies including Anaplan, AppDynamics, Aveksa, ComScore, Coremetrics, E*Trade, Intersect ENT, Natera, Predictive Systems, Postmates, Priceline, Peribit, Scopus, Spotify, SS&C, Xactly, and Zerto. To learn more, please visit www.harmonyvp.com.

Suppliers
Hovione Farmaciência SA Wholesale: Consumer Non-Durables/Sundries | Loures, LI

Hovione FarmaCiencia SA manufactures and distributes active pharmaceutical ingredients. Its services include contract manufacturing services, off-patent API products, proprietary product licensing, and supporting capabilities. The company was founded by Diane de Lancastre Houssemayne Du Boulay Villax, Ivan Villax, Nicholas de Horthy and Andrew Onody in 1959 and is headquartered in Loures, Portugal.

Element Materials Technology Ltd. Other Business & Consulting Services | London, GL

Element Materials Technology Ltd. operates a material testing laboratory. The company was founded in 2011 and is headquartered in London, the United Kingdom.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Smith & Nephew Plc Medical Products & Equipment - Watford, HR

Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It offers the following products and services: sports medicine joint repair; arthroscopic enabling technologies; trauma and extremities; other surgical businesses; knee and hip implants, and advanced wound care, wound bioactives, and wound devices. It operates through the United Kingdom, United States of America, and Other geographical segments. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Medtronic Plc Medical Products & Equipment - Dublin, DU

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Awards & Honors
Rank #39
2014
Forbes - America's Most Promising Companies
Sponsored by Forbes Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Intersect ENT, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Intersect ENT, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Intersect ENT, Inc..